#Caribou Biosciences#CRBU stock#Tina M. Albertson#Insider trading#CAR-T cell therapies#NASDAQ#Biotechnology investments
📌 Key Takeaways
Caribou Biosciences CMO sold $2,089 worth of company stock
CRBU stock has gained 32% over the past week
Albertson also acquired 55,000 shares and received options for 247,500 shares
Analysts view Caribou as undervalued with a $13 price target
📖 Full Retelling
Caribou Biosciences Chief Medical Officer Tina M. Albertson sold 1,066 shares of common stock on February 24, 2026, at a price of $1.96, for a total value of $2,089, as reported in insider trading data for the NASDAQ-listed biotechnology company. The stock has since climbed to $2.14, posting a remarkable 32% gain over the past week, according to market data. Despite this recent sale, Albertson's other recent activities suggest continued confidence in the company. On February 20, 2026, she acquired 55,000 shares of Caribou Biosciences common stock, which represent restricted stock units that vest in four equal annual installments beginning on February 20, 2027. Additionally, on the same day, Albertson was granted options to purchase 247,500 shares of Caribou Biosciences common stock at an exercise price of $1.80, with these options vesting monthly and full vesting occurring by February 20, 2030. InvestingPro analysis indicates that the stock currently appears undervalued based on its Fair Value assessment for the $203.76 million market cap biotech company. This positive assessment comes alongside analyst endorsement, as Clear Street has recently initiated coverage on Caribou Biosciences with a Buy rating and a price target of $13.00, expressing particular optimism about the company's development of off-the-shelf allogeneic CAR-T cell therapies.
# Insider Trading
**Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Nasdaq Stock Market (National Association of Securities Dealers Automated Quotations) is an American stock exchange, the second-largest by market cap on the list of stock exchanges, and the first fully electronic stock market. The exchange is based in Manhattan, New York City, and is among the most ...
Rachel Elizabeth Haurwitz (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry AMD stock surges 14% on Meta AI partnership deal Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) Caribou Biosciences CMO sells $2.1k in CRBU stock By Investing.com Insider Trading Published 02/24/2026, 08:58 PM Caribou Biosciences CMO sells $2.1k in CRBU stock 0 CRBU 11.46% Caribou Biosciences NASDAQ:CRBU Chief Medical Officer Tina M. Albertson sold 1,066 shares of common stock on February 24, 2026, at a price of $1.96, for a total value of $2,089. The stock has since climbed to $2.14, posting a remarkable 32% gain over the past week. An InvestingPro tip notes that stock price movements are quite volatile, which investors should consider when evaluating insider transactions. On February 20, 2026, Albertson also acquired 55,000 shares of Caribou Biosciences common stock with a value of $0. These shares represent restricted stock units that vest in four equal annual installments beginning on February 20, 2027. Additionally, on the same day, Albertson was granted options to purchase 247,500 shares of Caribou Biosciences common stock at an exercise price of $1.80. These options vest monthly, with full vesting by February 20, 2030. According to InvestingPro analysis, the stock currently appears undervalued based on its Fair Value assessment for the $203.76 million market cap biotech company. In other recent news, Caribou Biosciences has received a Buy rating from Clear Street, which has initiated coverage on the company with a price target of $13.00. Clear Street expressed optimism about Caribou’s development of off-the-shelf allogeneic CAR-T cell therapies. These therapies are believed to have the potential to compete commercially in the market. This development reflects a positive outlook from analysts at Cle...
